Methylglyoxal Antibody (MGO-1)

• Reactivity: Hu
• Applications: WB, ELISA, IHC
• Clone: MGO-1
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.1 mg/ml

Methylglyoxal Antibody (MGO-1) Summary

• Immunogen: Methylglyoxal-modified KLH
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunoassay
  • Immunohistochemistry-Paraffin
  • Western Blot
• Application Notes: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 0.2 um filtered solution in PBS, 0.1% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.1 mg/ml
• Purity: Protein G purified

Alternate Names for Methylglyoxal Antibody (MGO-1)

• 2-oxopropanal
• Pyruvaldehyde

Background

The monoclonal antibody MGO-1recognizes human MGO modified proteins. Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of methylglyoxal (MGO), as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. A number of studies have shown that MGO levels are significantly elevated in patients with Type 2 Diabetes- and correlates well with fasting plasma glucose and hemoglobin A1c (HbA1c) levels. Moreover, increased formation of the MGO is implicated in renal dysfunction and is known to be involved in the development of DN (diabetic nephropathy).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.